DekaBank Deutsche Girozentrale
RPRX icon

DekaBank Deutsche Girozentrale’s Royalty Pharma RPRX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.7M Hold
746,287
– – 0.06% 251
2026
Q1 		$36.4M Hold
746,287
– – 0.06% 251
2025
Q4 		$22.9M Hold
746,287
– – 0.04% 307
2025
Q3 		$26.1M Hold
746,287
– – 0.04% 288
2025
Q2 		$26.7M Sell
746,287
-3,057
-0.4% -$101K 0.05% 276
2025
Q1 		$22.8M Buy
749,344
+3,057
+0.4% +$96.9K 0.04% 291
2024
Q4 		$18.9M Hold
746,287
– – 0.03% 332
2024
Q3 		$20.8M Buy
746,287
+17,159
+2% +$475K 0.04% 319
2024
Q2 		$19.3M Sell
729,128
-20,216
-3% -$560K 0.03% 330
2024
Q1 		$22.5M Buy
749,344
+276,546
+58% +$8.15M 0.04% 302
2023
Q4 		$13.1M Sell
472,798
-6,826
-1% -$188K 0.03% 382
2023
Q3 		$13.2M Buy
479,624
+5,643
+1% +$168K 0.03% 373
2023
Q2 		$14.4M Buy
473,981
+15,334
+3% +$519K 0.03% 363
2023
Q1 		$16.2M Sell
458,647
-39,481
-8% -$1.46M 0.04% 323
2022
Q4 		$19.2M Buy
498,128
+216,827
+77% +$9.05M 0.05% 294
2022
Q3 		$11M Buy
281,301
+69,536
+33% +$2.97M 0.03% 356
2022
Q2 		$8.61M Sell
211,765
-1,587
-0.7% -$65.1K 0.03% 415
2022
Q1 		$8.52M Buy
213,352
+93,906
+79% +$3.69M 0.02% 451
2021
Q4 		$4.88M Buy
119,446
+9,619
+9% +$374K 0.01% 573
2021
Q3 		$3.97M Sell
109,827
-965
-0.9% -$37.5K 0.01% 587
2021
Q2 		$4.6M Buy
110,792
+2,698
+2% +$115K 0.01% 541
2021
Q1 		$4.62M Buy
108,094
+24,666
+30% +$1.17M 0.02% 503
2020
Q4 		$4.07M Buy
+83,428
New +$3.54M 0.02% 501
2020
Q3 		– Sell
-21,000
Closed -$1.02M – 1222
2020
Q2 		$1.02M Buy
+21,000
New +$1.04M 0.01% 651

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DekaBank Deutsche Girozentrale's RPRX Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its Royalty Pharma (RPRX) position steady in Q2 2026 at 746,287 shares worth $35.7M. The position accounts for 0.06% of the portfolio, ranked #251.

DekaBank Deutsche Girozentrale first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. The position peaked at $36.4M in Q1 2026. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • DekaBank Deutsche Girozentrale held 746,287 shares of Royalty Pharma worth $35.7M as of Q2 2026.
  • DekaBank Deutsche Girozentrale left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.06% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #251 holding.
  • DekaBank Deutsche Girozentrale first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • DekaBank Deutsche Girozentrale's Royalty Pharma position peaked at $36.4M in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.